Dr Gruenwald on Tumor Responses With Lenvatinib Plus Pembrolizumab in Advanced RCC

Viktor Gruenwald, MD, PhD, discusses key results from a post hoc analysis of the phase 3 CLEAR trial in advanced renal cell carcinoma, highlighting the clinical implications of these results.

Related Keywords

Germany ,West German ,Viktor Gruenwald ,German Cancer Center ,Essen University Hospital ,West German Cancer Center ,Medical Oncology ,Renal Cell Carcinoma ,Phase 3 Clear Trial Nct02811861 ,Lenvatinib ,Pembrolizumab ,Sunitinib ,